FBXO33 Inhibitors
FBXO33 inhibitors operate through various biochemical mechanisms to impede the functional activity of FBXO33. Compounds that target the PI3K-Akt and mTOR pathways are particularly significant, as they can lead to the suppression of downstream signaling events that FBXO33 is involved in. By inhibiting PI3K directly, the subsequent AKT signaling cascade, which is crucial for various cellular functions including the regulation of protein degradation, is disrupted. This disruption can diminish the ubiquitination activity of FBXO33, which plays a role in the degradation of proteins. Similarly, by inhibiting the mTOR pathway, especially mTORC1, the activity of FBXO33 can be indirectly decreased due to its involvement in downstream processes regulated by mTOR. Moreover, compounds that inhibit the proteasome prevent the degradation of ubiquitinated proteins, thereby indirectly affecting the turnover of proteins that FBXO33 targets for degradation.
Further inhibition mechanisms involve the MAPK family signaling pathways where p38 MAPK and JNK inhibitors can suppress pathways that influence FBXO33's activity. By targeting MEK1/2 enzymes within the ERK pathway, the activity of FBXO33 can be indirectly inhibited as it may function downstream of this pathway. Specific inhibitors of p70 S6 kinase, a component of the mTOR pathway, can also affect FBXO33's role in protein ubiquitination and degradation. Moreover, compounds that inhibit the calpain family of proteases, which are implicated in a wide array of cellular processes, can lead to the indirect inhibition of FBXO33 function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
This compound inhibits the PI3K-Akt pathway, which could reduce the ubiquitination activity of FBXO33 due to its role in the regulation of protein degradation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, leading to the suppression of the PI3K-AKT signaling pathway. Since FBXO33 is implicated in cellular processes regulated by this pathway, its activity can be indirectly inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that interferes with the mTORC1 signaling complex. FBXO33 is involved in pathways that are downstream of mTOR, and inhibition of mTORC1 can lead to a decrease in FBXO33 activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins, indirectly affecting the turnover of proteins targeted by FBXO33 for degradation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, which can suppress the MAPK pathway. FBXO33 could be indirectly inhibited due to its involvement in pathways associated with MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK family. By inhibiting JNK, the MAPK signaling pathway is affected, potentially leading to altered FBXO33 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, which impacts the ERK pathway. Since FBXO33 may function downstream of this pathway, its activity could be indirectly inhibited. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A selective NUAK1 inhibitor, which can affect cellular processes that FBXO33 might regulate, leading to a decrease in its functional activity. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
A specific inhibitor of p70 S6 kinase, a protein involved in the mTOR pathway. This inhibition could indirectly affect FBXO33's role in protein ubiquitination and degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A peptide boronate proteasome inhibitor, which by preventing proteasomal degradation of ubiquitinated proteins, can indirectly affect FBXO33's function. | ||||||